Evidence map›Paper›PMID 36365108›Full record

ArticlePharmaceutics2022

Clinical Efficacy of Temocillin Standard Dosing in Patients Treated with Outpatient Antimicrobial Therapy.

Evelyne Van den Broucke, Lore Thijs, Stefanie Desmet, Lotte Vander Elst, Matthias Gijsen, Marnix Mylemans, Otto Van de Gaer, Willy E Peetermans, Charlotte Quintens, Isabel Spriet

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Temocillin: A Narrative Review of Its Clinical Reappraisal.Antibiotics (Basel, Switzerland) · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Evelyne Van den BrouckePharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.
Lore ThijsPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.
Stefanie DesmetClinical Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Lotte Vander ElstPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.
Matthias GijsenPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-1378-3772
Marnix MylemansClinical Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Otto Van de GaerClinical Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Willy E PeetermansDepartment of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
Charlotte QuintensPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-6072-2596
Isabel SprietPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium.
KU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2020, EUCAST introduced breakpoints for temocillin. Based on these guidelines, reporting of temocillin susceptibility of

Indexed as

dosingEUCASTMICOPAT at hometemocillin

Identifiers

PMID36365108
PMCPMC9699557
OpenAlexW4307547641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.